Physician profile
Randolph Sanchez
NPI 1508244898
$7,172.95
in general payments reported to CMS, 2019-2025
45 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $122 · 2021: $1,075 · 2022: $106 · 2023: $925 · 2024: $1,962 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,466 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,466.15 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,502.77 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Abbvie INC. | $936.85 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $828.93 | 2022-2025 | |
| Janssen Biotech, INC. | $611.73 | 2021-2025 | Tremfya |
| Ucb, INC. | $454.50 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $398.05 | 2021-2025 | Taltz, Zepbound, Omvoh |
| Janssen Scientific Affairs, LLC | $340.50 | 2024-2025 | Tremfya |
| Pfizer INC. | $272.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $230.24 | 2020-2025 | Benlysta, Trelegy Ellipta, Nucala |
| Corcept Therapeutics | $215.61 | 2024-2025 | Korlym |
| Horizon Therapeutics Plc | $147.03 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $138.71 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $112.17 | 2024-2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $111.03 | 2023-2025 | Strensiq |
| Radius Health, INC. | $106.23 | 2024-2025 | Tymlos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.